Medtronic Initiates U.S. Trial to Evaluate the Use of Subcutaneous Peripheral Nerve Stimulation for Chronic Back Pain

[at noodls] – MINNEAPOLIS – April 11, 2013 – Medtronic, Inc. (NYSE: MDT) today announced the first patient enrollments in the SubQStim II pivotal clinical trial to pursue U.S. Food and Drug Administration (FDA) approval … more

View todays social media effects on MDT

View the latest stocks trending across Twitter. Click to view dashboard

See who Medtronic is hiring next, click here to view